Effects of the treatment with acarbose in elderly overweight type 2 diabetic patients in poor glycemic control with oral hypoglycemic agents or insulin

Archives of Gerontology and Geriatrics

Volumn 31, Issue 1, 2000, Pages 27-34

  Sangiorgio, L ^a   Attardo, T ^a   Condorelli, L ^a   Lunetta, M ^a  

^a Univ C   (Italy)

Author keywords

Acarbose; Glycemic control; Type 2 diabetes

Indexed keywords

ACARBOSE; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL;

EID: 0033827961     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4943(00)00064-9     Document Type: Article

References (25)

1. Buchanan D.R., Collier A., Rodrigues E., Millar A.M., Gray R.S., Clarke B.F. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non obese non insulin-dependent diabetes. Eur. J. Clin. Pharmacol. 34:1988;51-53.
2. Chiasson J.L., Josse R.J., Hunt J.A., Palmason C., Rodger N.W., Ross S.A., Ryan E.A., Tan M.H., Wolever T.M.S. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann. Intern. Med. 121:1994;928-935.
3. Coniff R.F., Shapiro J.A., Timothy B., Seaton B. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch. Intern. Med. 154:1994;2442-2448.
4. Coniff R.F., Shapiro J.A., Robbins D., Kleinfield R., Seaton T., Beisswenger P., McGill J.B. Reduction of glicosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care. 18:1995;817-824.
5. Coniff R.F., Shapiro J.A., Seaton T.B., Bray G.A. Multicenter, placebo-controlled trial comparing acarbose (Bay g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am. J. Med. 98:1995;443-451.
6. Coniff R.F., Shapiro J.A., Seaton T.B., Hoogwerf B.J., Hunt J.A. A double-blind placebo-controlled trial evaluating the safety and efficacy af acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care. 8:1995;928-932.
7. 1c. Diabetes. 27:1978;102-107.
8. Garancini M.P., Calori G., Ruotolo G., Manara E., Izzo A., Ebbli E., Bozzetti A.M., Boari L., Lazzari P., Gallus G. Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia. 38:1995;306-313.
9. Genuth S. Insuline use in NIDDM. Diabetes Care. 13:1990;1240-1264.
10. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin dependent and insulin-dependent diabetes mellitus. Ann. Intern. Med. 124(1 pt 2):1996;104-109.
11. Hanefeld M., Fischer S., Schulze J., Splenger M., Wargenau M., Shollberg K., Fucker K. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care. 14:1991;732-737.
12. Kadish A.H., Little R.L., Sternberg J.C. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin. Chem. 14:1968;116-120.
13. Klein R., Klein B.E.K., Mors S.E. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 15:1992;1875-1921.
14. Puls W., Keup U., Krause H.P., Thomas G., Hoffmeister F. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity and hyperlipoproteinaemia. Naturwissenschaften. 64:1977;536.
15. Puls W., Keup U., Krause H.P., Muller L., Schmidt D.D., Thomas G., Truschett E. Pharmacology of a glucosidase inhibitor. Horm. Res. 7:1980;235-247.
16. Reaven G.M., Lardinois C.K., Greenfield M.S., Schwartz H.C., Vreman H.J. Effects of acarbose on carbhydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care. 13(Suppl. 3):1990;32-36.
17. Rodier M., Richard J.L., Monnier L., Mirouze J. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus. Diabetes Metab. 14:1998;12-14.
18. Rosak C. Acarbose treatment and sulphonilurea secondary failure. Creutzfeldt W. Acarbose for the Treatment of Diabetes Mellitus. 1988;156-161 Springer, Berlin.
19. Rosak C. Glucosidase inhibition and sulphonylurea secondary failure. Diabetes Nutr. Metab. 3(Suppl. 1):1990;59-62.
20. Rossetti L., Giaccari A., De Fronzo R.A. Glucose toxicity. Diabetes Care. 13:1990;610-630.
21. Savagnone E., Cappello F., Caruso V., Galvano L., Mangione G., Nicolosi G., Raimondo F.C., Schirò V., Spicola L., Spinelli M., Sunseri V., Gargano F. Indagine epidemiologica sul diabete mellito nella popolazione di Pantelleria (Sicilia). G. Ital. Diabetol. 5:1985;71-80. Note preliminari.
22. Schmidt D.D., Frommer W., Junge B., Muller L., Wingender W., Truscheit E. a-Glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften. 64:1977;535.
23. Study design, progress and performance. Diabetologia. 14:1991;877-890. UKPDS 8.
24. Tight blood glucose control and risk of macrovascular and microvascular complications in type 2 diabetes. Br. Med. J. 317:1998;703. UKPDS 38.
25. Van Gaal L., Nobels F., De Leeuw I. Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. Z. Gastroenterol. 29:1991;642-644.